- Home
- IMPP vs PRQR Comparison
IMPP vs PRQR Comparison
Compare IMPP & PRQR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | IMPP | PRQR |
|---|---|---|
| Founded | 1981 | 2012 |
| Country | Greece | Netherlands |
| Employees | 49 | N/A |
| Industry | Marine Transportation | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 169.2M | 167.5M |
| IPO Year | N/A | 2014 |
Fundamental Metrics
Financial Performance| Metric | IMPP | PRQR |
|---|---|---|
| Price | $4.39 | $1.48 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 1 | 5 |
| Target Price | N/A | ★ $6.80 |
| AVG Volume (30 Days) | ★ 846.8K | 291.4K |
| Earning Date | 03-06-2026 | 03-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $51.79 | $18.88 |
| Revenue Next Year | $6.97 | N/A |
| P/E Ratio | $3.68 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $2.12 | $1.08 |
| 52 Week High | $6.57 | $3.10 |
Technical Indicators
Market Signals| Indicator | IMPP | PRQR |
|---|---|---|
| Relative Strength Index (RSI) | 50.74 | 43.57 |
| Support Level | $4.28 | $1.33 |
| Resistance Level | $4.84 | $1.58 |
| Average True Range (ATR) | 0.23 | 0.12 |
| MACD | -0.05 | -0.03 |
| Stochastic Oscillator | 37.13 | 26.00 |
Price Performance
Historical ComparisonAbout IMPP Imperial Petroleum Inc.
Imperial Petroleum Inc is a provider of international seaborne transportation services to oil producers, refineries, and commodities traders. It owns and operates a fleet of six medium-range product tankers that carry refined petroleum products such as gasoline, diesel, fuel oil, and jet fuel, as well as edible oils and chemicals.
About PRQR ProQR Therapeutics N.V.
ProQR Therapeutics NV is a biopharmaceutical company. It discovers and develops RNA therapeutics for patients with severe genetic rare diseases such as cystic fibrosis, Leber congenital amaurosis type 10, and dystrophic epidermolysis bullosa. The only reportable segment of the company is the discovery and development of different, RNA-based therapeutics. Geographically, the company operates in United States.